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                                   ABSTRACT 
 
Objective: Literature review to evaluate the extent to which Bioinformatics has facilitated 
the drug discovery and development process from an economic perspective 
 
Problem: A plethora of genomic and proteomic information was uncovered by the U.S 
Human Genome Project (HGP). Despite the projected impact that Bioinformatics and 
Pharmacogenomics were projected to have in the drug discovery and development 
process, the challenges facing the pharmaceutical companies – in this regard, still persist. 
 
Design: An extensive integrated literature review of library resources such as MEDLINE, 
ERIC, PsychInfo, EconLit, Social Services Abstracts, ABI/INFORM and LISA (all 1990 
– Present). These electronic databases were researched because of their focuses on the 
healthcare sector, medical and scientific innovations, economic modeling and analysis, 
bioinformatics and computational biology, applied social research and technology 
applications. Semi-structured interviews of Bioinformatics professionals were also 
conducted to complement the literature review. Also, Internet-based databases from 
reliable resources were also researched resulting in serendipitous discoveries.  
 
Sample: Published English language reports of studies and research carried out 
worldwide from 1990 to 2004, relating to drug discovery and development. 
 
Selection criteria: Primary focus was on research publications and journals that identify 
and discuss the practice of Bioinformatics, especially in the area of drug discovery and 
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development. Premium was placed on articles and publications that discussed the 
economic impacts of Bioinformatics in the drug discovery process.  
 
Results: Though the goals of Bioinformatics have been clearly defined, and the discipline 
is widely practiced in the pharmaceutical industry, this study has not found any definite 
attempts to evaluate its economic and regulatory impact specifically in facilitating the 
drug discovery and development process, and the delivery of personalized drugs. 
 
Discussion: Bioinformatics and Pharmacogenomics are the new facets of the ever-
evolving drug discovery and development process. It may still be a while before their full 
impact and potential is attained.  
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                                      CHAPTER 1 
INTRODUCTION 
In the April 1953 edition of the scientific journal Nature, James Watson and Francis 
Crick published a landmark paper describing for the first time the structure of the 
Deoxyribonucleic acid (DNA) molecule. Though the term ‘Double Helix’ was not used 
in that paper, the proposed double-helical structure of the DNA came to be known as the 
Watson and Crick model. Exactly half a century – to the month – after this historical 
publication, the US Human Genome Project announced that the human genome sequence 
was “substantially complete” (Malorye, 2003).  Fittingly, the inaugural director of the 
Human Genome Project (1990-1992) was James Watson, one of the two men who a half-
century earlier had pioneered the modern concept of the genetic basis of life.  
With the advent of the ubiquitous US Human Genome Project (HGP), it became apparent 
in the scientific community, that computer technology would be required to process the 
plethora of data uncovered from the human genetic makeup. The immediate need as 
described by the National Center for Biotechnology and Information (NCBI), was to 
‘store, organize, analyze, and integrate vast quantities of diverse data, such as DNA 
and protein sequences, gene and chromosome maps, and protein structures’ that was 
being uncovered by the project (NCBI, 2003). The information harnessed from this 
process, the NCBI asserted, was necessary to propel among other things, the efficient 
discovery of drugs and drug targets, and the elucidation of disease and health conditions 
(NCBI, April 2003). The unique confluence of molecular and genetic biology and 
computer technology – otherwise known as Bioinformatics – became the immediate 
solution as it enabled the “application of information technology to the management of 
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biological data” (Gibas et al., 2001; NCBI, 2003; Samudhram, 2003). The NCBI defined 
Bioinformatics as the field of science where “biology, computer science and information 
technology merge to form a single discipline” (NCBI, 2003). Bioinformatics continues to 
be a novel concept, generating different but related fields of research and development. 
Some of those include Pharmacogenomics (the application of genomic approaches and 
technologies to the identification of drug targets), Proteomics (the qualitative and 
quantitative studies of gene expression at the level of the functional proteins themselves) 
and a host of other –omics such as Transcriptonomics that have characterized the 
genome-classification era (Hofestadt, 2002; Mendible, 2003; NCBI, 2003; 
Whittaker,2003). These areas of research are all Bioinformatics applications. 
Bioinformatics quickly assumed a larger role in the processing of the genetic information 
with the hope that the genetic basis of health and disease would be unraveled, resulting in 
the efficient discovery of tailored and targeted drugs.  
Targeted drugs refer to the drugs that have been designed specifically to act on particular 
genes and their corresponding proteins, where these genes and proteins have been 
identified to be responsible for certain disease conditions (Boswell, 2002; Whittaker, 
2003). Targeted drug development is particularly applicable in the treatment of cancers, 
where the drugs are designed to directly target molecular abnormalities that lead to the 
growth of tumors (Prows & Prows, 2004).  
Tailored drugs on the other hand refer to drugs designed to address the needs of a 
specified genetic sub-group of the entire population (Rioux, 2000; Hall, 2003). This 
practice, also referred to as pharmacogenetics (or pharmacogenomics) is based on the 
premise that genetic variations within any given population dictates that individuals, or 
 7
sub-groups within any given population will respond differently – or not even respond at 
all – to the same medication (Rioux, 2000; Hall, 2003). Pharmacogenomics is the study 
of how genes affect a person’s response to drugs. This relatively new field combines 
pharmacology (the science of drugs) and genomics (the study of genes and their 
functions) to develop effective, safe medications and doses that will be tailored to a 
person’s genetic makeup (Mendible, 2003).  
 
The specific aim of this thesis is to review literature that addresses the socio-economic 
impact that Bioinformatics and Pharmacogenomics have or can have on the drug 
discovery and development process. Bioinformatics and other related fields such as 
Pharmacogenomics are viewed by some writers as distinct areas of research (Lim, 1997; 
Mahlich et al., 2001), while some others see Pharmacogenomics as the application of 
Bioinformatics (Myers and Baker, 2001; Whittaker, 2003). Nightingale (2000) classified 
Bioinformatics and related fields as “bioinformatics and bioinformatics technologies” and 
posits that they “have allowed pharmaceutical firms to exploit economies of scale in 
experimentation.”  In concurrence, Overby (2001) adds that technologies “grouped under 
the umbrella of bioinformatics … involve the use of computers to store, organize, 
generate, retrieve, analyze and share genomic, biological and chemical data for drug 
discovery”. The view of this thesis is that Bioinformatics is an all-encompassing field that 
defines any confluence of molecular biology and computer information science 
(Counsell, 2004). Bioinformatics as thus, would play a significant role in drug target 
discovery (the discovery of suitable drug targets in the human DNA) – by mining and 
analyzing genomic and proteomic data etc – and drug target validation (the validation, 
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through experimentation that a drug target is the appropriate one) – by linking targets to 
biological and drug function (Whittaker, 2003).  
 
This thesis is arranged into 6 distinct chapters. The introductory chapter (preceded by an 
abstract overview) is immediately followed by the Background and Significance. Here, 
the background is reviewed and the significance of the thesis is discussed. 
Next is the problem statement and purpose. The problem, once identified, will enable the 
formulation of the purpose. 
The Methods and Design chapter will reveal the ways and means by which information is 
gathered and selected. The data sources are also revealed. 
The Results of the literature review are presented in the following chapter. The 
concluding chapter is the Discussion and Future Work. 
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CHAPTER 2 
     BACKGROUND AND SIGNIFICANCE 
 
The Merriam-Webster online dictionary defined a drug as “a substance intended for use 
in the diagnosis, cure, mitigation, treatment, or prevention of disease…or as a component 
of a medication”. The origin of the use of potent compounds for the mitigation of disease 
conditions predates both the pharmaceutical industry and history. The discovery of drugs 
historically has been serendipitous (Ratti & Trist, 2001). For most of its history, drug 
discovery has been a product of trial and error, “guided as much by the intuition and 
serendipity of chemists, biologists and physicians as by any rational linear process” 
(Papanikolaw, 1999). Long before the pharmaceutical industry existed, drugs were 
discovered by accident and their uses passed down by verbal and written records (Ratti & 
Trist, 2001). According to Boa (2003), “Throughout history people have found by trial 
and error which berries, roots and barks could be used for medicinal purposes to alleviate 
symptoms of illness”. For example, the Willow bark, which contains salicin, was used as 
a fever reducer in the same vein as the Cinchona bark from which quinine was discovered 
(Boa, 2003). The drug discovery process would continue to be by trial and error until 
early - mid 20th century when the pharmacological basis of diseases and drugs were 
beginning to be defined (Boa, 2003). Even then, serendipity was sought in the 
pharmaceutical industry as evident by the screening of known compounds or randomly 
testing any available molecules. Such successful drugs as chlorpromazine, meprobamate, 
and benzodiazepines were discovered in this way (Ratti & Trist, 2001).  
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In this process, lead molecules found by chance or from screening the chemical diversity 
available were then optimized by medicinal chemists to produce candidates, which were 
passed to development and eventually into the market (Fig 1).  However, this approach at 
that time suffered from a lack of sufficient molecules with high enough structural 
diversity among other factors. 
A more rational approach was later developed to improve on this process. In this 
elongated approach which became mainstream in the 80s, in vitro assays using animal 
tissues (rather than previously used in vivo methods) became central in the process for 
giving valuable information on structure–activity relationships and eventual 
pharmacophore construction (Fig 2). In this way, if the lead molecule fails there is 
sufficient information around structure and activity to allow the cause for failure to be 
extricated from the molecule. 
Fig 1: Drug Discovery in the 50s and 60s 
 
Source: Ratti & Trist (2001) 
 
Fig 2: Drug Discovery in the 80s 
 
Source: Ratti & Trist (2001) 
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 Fig 3: Drug Discovery Today (90s and beyond) 
 
Source: Ratti & Trist (2001) 
 
The projection that Bioinformatics will lead to the era of tailored and targeted drugs has 
been expressed by many scholars including Van Arnum (1998), Papanikolaw (1999), 
Attwood et al. (2003), Lindpaintner (2003) and Evans et al. (2004). Evans et al. (2004) 
described this impact as the development of “subpopulation-specific drug. While the 
current practice of drug development addresses the needs of the majority of the 
population, scientific data has shown that people vary in their response to the same drug 
(Nuffield Council on Bioethics, 2003; Evans et al. 1999, 2004; Prows & Prows, 2004). 
Few drugs are effective for everyone; all may cause adverse reactions or occasionally 
death for individuals in sub-groups of the general population (Prows & Prows, 2004). In 
fact, in 1994, it is estimated that at least 106,000 people died from adverse reactions to 
"safe," FDA-approved drugs (Lazarou et al., 1998). This figure includes only hospitalized 
patients and does not include those people who died because of medical error such as the 
prescribing of the wrong drug, which also accounts for some 100,000 deaths every year 
(Kohn et al., 1999). Some of the variation between individuals in response to drugs is due 
to differences in their genetic make-up (Nuffield Council on Bioethics, 2003; Evans et al. 
1999, 2004; Prows & Prows, 2004). This variation generally referred to as genetic 
polymorphisms can be seen as a “stable difference in DNA sequence at the same locus (a 
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specific position in the genome) among individuals” (Rioux, 2000). The differing DNA 
sequence at the same position – known as alleles – can lead to a difference in the 
expression of the genotype (Rioux, 2000). Genotype refers to a person’s specific allelic 
composition while the Phenotype refers to the observable or measurable manifestation of 
a person’s genotype, either by itself or in coordination with environmental factors (Rioux, 
2000; Prows & Prows, 2004). The most common form, or allele, of a gene found within a 
population is known as the wildtype allele. Alternate forms result from a change in the 
gene’s chemistry or structure. It is estimated that 99.9% of the human genome sequence 
is identical in all individuals, despite observable differences. Differences in the human 
genome, or DNA alterations, are called mutations if they are rarely found within a 
population and polymorphisms if they are more common – that is, found in 1% or more 
of a population (Rioux, 2000; Prows & Prows, 2004). In scientific literature, a gene 
alteration is mostly regarded as a mutation if it leads to a disease condition or a 
polymorphism if it leads to no observable effects (Prows & Prows, 2004). Strictly 
speaking however, both mutations and polymorphisms differ mainly in their relative 
frequencies of occurrence in the general population, and can have no effect, a beneficial 
effect, or lead to a disease (Rioux, 2000; Bell, 2004; Prows & Prows, 2004). Similarly, 
mutations and polymorphisms lead to very diverse differences in the ways that 
individuals react to drugs when administered (Rioux, 2000; Goldstein et al., 2003; Bell, 
2004; Prows & Prows, 2004). Tsai and Hoyme estimate that more than 20 
polymorphisms have been identified in drug metabolizing enzymes alone, often with 
diverse frequencies among individuals from various racial and ethnic backgrounds (Tsai 
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and Hoyme, 2002). According to Goldstein et al., 2003, the number is far more. In fact 
they state as follows: 
Forty-two polymorphisms that have been significantly associated 
with drug response in at least two studies show that obvious candidate 
 genes, such as drug-metabolizing enzymes and drug targets, often carry  
important pharmacogenetic polymorphisms, and that such polymorphisms 
 are often owing to common alleles. 
 
Tsai and Hoyme (2002) went on to identify several mechanisms through which 
polymorphisms can cause alterations in drug effect. These include: 
• Extended pharmacological effect – whereby drugs have more extended effects 
than anticipated 
• Adverse drug reaction 
• Lack of pro-drug activators – whereby the drugs become inactivated and therefore 
ineffective 
• Drug toxicity and 
• Increased or decreased effective dose 
 
The correlation between genetics and drug responses has been described in scientific 
literature for many decades. In fact, according to Tsai & Hoyme (2002) Vessel and Page 
in their 1968 investigation of drug responses in the general population showed “genetic 
influence on drug metabolism, as drug half-lives were markedly alike in monozygotic 
[identical] twins and varied widely in dizygotic [non-identical] twins and the 
population at large” [Emphasis mine]. Monozygotic twins share the same identical 
genomes, while dizygotic twins share genomes just like non-twin siblings. 
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Despite the available information that closely links drug reaction with genetic identities, 
the current practice of drug discovery generally does not allow a pharmacogenomic 
strategy – a strategy that applies the need to have drugs designed to cater for the needs of 
the various genotypic sub-groups of the population. Drugs are generally designed by 
applying a ‘majority rule’ strategy where discovery and development are geared towards 
the satisfaction of the needs of the major genetic sub-groups of the population. Prows & 
Prows (2004) identified this application of the ‘average dose’ to be enormously costly to 
society. They observe as follows: 
  “Currently, most medications are prescribed without 
                                                   assurance of efficacy in a given individual. 
                                                   Often, several drugs must be tried to find one that 
                                                   works. Adverse drug reactions are prevalent and 
   account for hospital expenditures estimated at up to 
                                                   $5.6 billion annually.” 
 
The rising costs and inconveniences of prescribing drugs to patients who may well end up 
as non-responders is generating concern and ultimately interest in research in this area 
(Burke et al., 2004; Prows & Prows, 2004). The possibility of mitigating – by means of a 
pharmacogenomic approach to drug discovery – the high healthcare care costs associated 
with adverse drug responses has generated strong interests not only in medicine, science 
and the academia, but also within the pharmaceutical and health insurance industries 
(Burke et al., 2004; Prows & Prows, 2004). The interest expressed by third-party payers – 
health insurance companies – suggests that this approach may lead to an overall decrease 
in the cost of healthcare (Prows & Prows, 2004). 
Rioux (2000) while championing a pharmacogenomic approach to drug development 
notes the distinction between the genetic polymorphism in patients resulting in them 
requiring varying dosages of the same drugs for the desired effects to be achieved, and 
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& Prows, 2004). 
 The genetic variations and the resultant effects on the metabolisms of drug substances 
are often not trivial, as seen from the observation of Rioux (2000) below: 
   “Many drug-metabolizing enzymes exhibit polymorphic expression… 
                but the principal enzymes causing hereditary variations in drug  
                metabolism found in the liver belong to the cytochrome P-450 
               (CYP) isoenzyme system. Polymorphic expression of at least three of 
             these isoenzymes divides the human population into two groups: 
               "poor" metabolizers, whose genes express dysfunctional or inactive 
               enzymes, and "extensive" metabolizers, whose genes express enzymes 
               with normal activity. Poor metabolizers account for 3-7% of whites  
              ; the distribution of these polymorphisms can be very different in  
other ethnic groups. Furthermore, the magnitude of variation in drug 
                metabolism between poor metabolizers and extensive metabolizers is 
                normally not trivial; the rate at which many drugs are metabolized 
                may vary 10-fold to 100-fold between these two groups of people”   
Prows & Prows (2004) included a third group of metabolizers – the normal, in addition to 
the enhanced and the deficient. Figure 1 below (Prows & Prows, 2004) shows the drug 
metabolizing differences between the various drug-metabolizing sub-groups. 
 
 
 
 
 
 
 
 
Fig. 1: The Effects of Genetic Variation on Drug-Metabolizing Enzymes (Prows & 
Prows, 2004) 
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 Although there seems to be sufficient evidence to show that the traditional drug discovery 
and development process as commonly practiced today may not cater for everyone’s 
needs (Rioux, 2000; Michalowski, 2001; Evans et al. 2004), there are several factors 
mitigating the effectiveness of applying Bioinformatics in the quest for targeted and 
tailored drug development. Some of these factors are economic (Michalowski, 2001; 
Evans et al. 2004) ethical (Rioux, 2000; Michalowski, 2001; World Health Organization, 
2002; Nuffield Council on Bioethics, 2003), legal (Michalowski, 2001; World Health 
Organization, 2002; McCubbin, 2003) and political (Michalowski, 2001; World Health 
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Organization, 2002). The ethical, legal and political issues concerning the application of 
Bioinformatics in pharmacology are too vast to be covered in this thesis. For more 
information on these, please refer to " Ethical, legal and social implications (ELSI) of 
human genomics" (http://www.who.int/genomics/elsi/en/) a World Health Organization 
(WHO) report.  
The economic factors however will be reviewed in this paper. The importance of 
evaluating the economic factors that impact the application of Bioinformatics in drug 
discovery and development seems evident. When a pharmaceutical company embarks on 
a search for a new drug or new chemical entity, the overwhelming motivation for this is 
the quest for profits (Gilbert et al., 2003; Rasmussen, 2003; Tait & Mittra, 2004). A great 
majority of pharmaceutical companies are publicly traded investor-owned profit-oriented 
companies (Gilbert et al. 2003; Rasmussen, 2003). The high and rising costs of drug 
discovery and development combined with lower average margins and shorter exclusivity 
(patent protection) periods have forced the pharmaceutical companies to rely heavily on 
blockbuster drugs – drugs that generate sales upwards of $1billion per year (Gilbert et al., 
2003; Klein & Tabarrok, 2003; Rasmussen, 2003; Tait & Mittra, 2004). This business 
model – the quest for blockbuster drugs – is investor driven (Keefer, 2003). With the 
increasing costs and the need to maintain healthy drug-candidate pipelines, 
pharmaceutical companies are forced to discover ways of becoming more innovative and 
cost effective (Papanikolaw, 1999; Ratti & Trist, 2001; Keefer, 2003; Tait & Mittra, 
2004). Bioinformatics and related technologies have been widely considered in the 
pharmaceutical industry in part because they are expected to make the drug discovery 
process less tedious (Duggan et al., 2000), more time efficient (Ratti & Trist, 2001), more 
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successful (Zemlo, 2004) and more cost-effective (Overby, 2001). It [Bioinformatics] 
will allow pharmaceutical firms to exploit “economies of scale in experimentation” 
(Nightingale, 2000) through high throughput screening (Ratti & Trist, 2001). Investments 
in Bioinformatics are on the rise. Experts project that the Bioinformatics market would 
grow from an estimated $290 million in 1998 to about $1.7billion in 2005 (Papanikolaw, 
1999). 
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CHAPTER 3 
PROBLEM STATEMENT AND PURPOSE 
Problem Statement 
Despite all the investments and high expectations from Bioinformatics, the 
pharmaceutical industry has not shown significant change – if at all, in the drug discovery 
and development process (Lindpaintner, 2003). This may be because the practice of 
Bioinformatics is relatively new and has only attained prominence in the years following 
the particl completion of the HGP (Lindpaintner, 2003). Bioinformatics has not had the 
impact it was expected to have – an impact that many still expect and project 
(Lindpaintner, 2003). The pharmaceutical industry continues to witness rising costs (by 
some estimates, as high as 55% in the last 5 years) and withdrawals of drugs from the 
market after they had been approved and commercialized – due to multiple documented 
cases of drug toxicity (Gilbert et al., 2003; Tait & Mittra, 2004). 
The drug discovery and development challenges facing the pharmaceutical industry have 
been noted by several writers (Papanikolaw, 1999; Duggan et al., 2000; Gilbert et al., 
2003; Klein & Tabarrok, 2003; Rasmussen, 2003; Tait & Mittra, 2004). The challenges 
range from – among others, the high cost of drug discovery and development, the lengthy 
and risky trials and approval process (leading to a shrinkage of the patent protection 
period), the occasional withdrawal of previously approved drugs from the market and the 
innovation gap resulting from the dogged quest for blockbuster drugs (Papanikolaw, 
1999; Duggan et al., 2000; Gilbert et al., 2003; Klein & Tabarrok, 2003; Rasmussen, 
2003; Tait & Mittra, 2004). Bioinformatics was widely projected to invigorate the 
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identification of drug targets (Papanikolaw, 1999; Overby, 2001; Ratti & Trist, 2001; 
Keefer, 2003; Tait & Mittra, 2004; Zemlo, 2004). The fact that these problems remain 
mostly unsolved despite significant Bioinformatics investments is an indication of a 
larger problem (Lindpaintner, 2003).  
The specific problems as identified by this thesis are as follows: 
• There are challenges facing the pharmaceutical industry concerning drug 
discovery and development. The industry relies heavily on a “Blockbuster drug” 
development strategy, where a drug is designed to meet the needs of several 
million people. These drugs are more profitable and meet the needs of the profit-
seeking shareholders of the pharmaceutical companies.  
• A consequence of the blockbuster model is the “innovation gap” in drug 
discovery and development. Most blockbuster drugs address medical needs for 
which drugs have already been developed. For the most part, new chemical 
entities (NCEs) or drugs are not developed in this model. 
• The direct impact of the innovation gap is the neglect of drugs for “rare” diseases. 
The drugs for many diseases that are not prevalent in the general population have 
been neglected. By definition, a rare disease in the United States is one suffered 
by 200,000 people or less. In reality, pharmaceutical companies mostly 
concentrate only on blockbuster drugs, which are taken by 20 million or more 
people. This means that a significant number of people have no choice but to take 
drugs that are not targeted for the treatment of their diseases. 
• Bioinformatics and related technologies have been widely touted to be the 
solution to the pharmaceutical industry challenges. To this end, investments in 
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Bioinformatics have in recent years been on the rise. The number of colleges and 
universities awarding Bioinformatics degrees in the United States alone has 
increased from 27 in 2002, to 50 in 2003 and 71 as of July 2004. Despite the 
increasing interest in Bioinformatics and related technologies, the drug discovery 
and development problems still persist 
• The changes that may be required to ensure the success of Bioinformatics strategy 
have not been made. The pharmaceutical industry continues to perpetuate the 
blockbuster model and is still not attentive to the needs of sub-groups of the 
population, stratified according to their genetic profiles. 
• The FDA, the governmental approval authority continues to test all drugs for use 
by the general population. Potential drugs that may be efficacious for a segment 
of the population, and be non-effective for other segments are doomed to failure. 
This testing and approval process is partly responsible for the high cost of drug 
discovery and development, and the alienation of many sufferers of rare diseases. 
 
Purpose 
This thesis is a review of existing literature on Bioinformatics, and its related sciences, 
particularly Pharmacogenomics and Pharmacogenetics with an emphasis on publications 
and research materials that discuss drug discovery and development. The thesis will 
assess the economic and regulatory factors that determine the current practice of drug 
discovery and development and how well these approaches fit Bioinformatics-engineered 
drug discovery and development. From the background information provided, it can be 
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inferred that Bioinformatics may lead to a more efficient generation of tailored and 
targeted drugs. This thesis will review the merits or demerits of that perspective.  
The literature review is complimented with semi-structured interviews of experts in the 
field as a means to verify and validate the findings of the literature review.  
The review of literature is from a socio-economic perspective. Ultimately, the 
development of drugs is for the treatment of diseases suffered in the general population. 
The costs of these drugs are passed on to the final consumers, and by implication, any 
factors that affect the cost of the development and discovery of these drugs will directly 
impact – positively or negatively – society. 
The specific purposes of the literature review include: 
• To understand the current prevailing process of drug discovery. This is an 
evaluation of the current practices that generally follow a traditional non-
Bioinformatics approach to drug discovery including the testing and approval 
process by the appropriate government agencies. 
• To evaluate the current model of cost evaluation of the drug discovery and 
development process.  
• To understand the propositions of a Bioinformatics and Pharmacogenomic 
approach to tailored and targeted drug discovery and development. 
• To review the differences between the traditional approach and the 
Bioinformatics approach, with an emphasis on overall costs evaluation  
 23
 CHAPTER 4 
METHODS AND DESIGN 
The findings of this thesis are the result of an integrated literature review. This chapter 
details the sources for the reviewed data, the search terms and result sets and the 
selection/inclusion criteria.  
Data Sources 
In order to provide an integrated results set, the following different databases were 
selected as data sources: 
 
? MEDLINE (1990 – 2004)  
? ERIC (1990 – 2004)  
? EconLit (1990 – 2004)  
? ABI/INFORM (1990 – 2004)  
The databases are repositories for different genres of data, and were selected for their 
various focuses on medical science and technology, health information and education, 
social sciences and economics. The rationale for the selection of each of these databases 
is explained below. 
MEDLINE is a bibliographic repository for a wide array of journals, articles and 
publications on medicine, nursing, dentistry, veterinary medicine, the health care system 
and pre-clinical sciences. This data source was selected because of its concentration on 
medical and healthcare related articles. Bioinformatics and related technologies are 
inclusive of the overall medical sciences genre. 
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ERIC, the Educational Resource Information Center is a national information system 
supported by the U.S. Department of Education, the National Library of Education, and 
the Office of Educational Research and Improvement. With Bioinformatics gaining 
prominence in scientific literature, it is being widely introduced into academic 
curriculums 
EconLit, published by the American Economic Association, provides bibliographic 
coverage of a wide range of economics-related literature. An expanded version of the 
Journal of Economic Literature (JEL) indexes of journals, books, and dissertations, 
EconLit covers both economic theory and application. Bioinformatics and related 
technologies can have direct and significant impacts on the economics of healthcare. 
Health, education, and welfare economics are some of the identified subject coverage 
areas for the EconLit bibliographic database. 
ABI/INFORM contains content from thousands of journals that help researchers track 
business conditions, trends, management techniques, corporate strategies, and industry-
specific topics worldwide. This data source was selected because of its publications on 
the pharmaceutical industry and the business models therein. It also contains up to date 
information on the news and current affairs of the pharmaceutical industry. With other 
databases, current affairs concerning Bioinformatics from trade publications and 
magazine articles are relatively rare. 
The World Wide Web (www) was also a source for latest, but sometimes fugitive 
Bioinformatics information. Considering the relative newness of Bioinformatics in 
mainstream of scientific literature, the WWW, a hyper-linked document repository, 
independent of geographic locations allows for current research publications and articles 
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to be readily available. Articles from the World Wide Web however need be considered 
with care, as the integrity of such can sometimes be difficult to verify. 
Semi Structured Interviews were also conducted. Bioinformatics has just recently been 
gaining prominence in the Pharmaceutical industry and is increasingly being employed in 
the drug discovery and development process. Early adopters of Bioinformatics techniques 
and practices were interviewed to gather feedback on its application. These interviewees 
– practicing Bioinformaticians – were very helpful both in complementing the relative 
scarcity of literature and in validating the results of the literature review. 
 
 
Search Terms and Selection Criteria 
 
Search Terms 
A first search was carried out in Medline using the term “Bioinformatics”. The Medline 
search process mapped the search term to the thesaurus term “Computational Biology”. A 
review of the scope of this mapped term showed that Computational Biology was 
introduced as a subject heading in 1997, and encompasses all methods and theories, 
relating to Molecular Biology, concerned with the development of techniques for the 
collection and manipulation of biological data, and the use of such data to make 
biological discoveries or predictions. This search term is used for Bioinformatics and is 
related to the search term Medical Informatics. Using the “Computational Biology” 
search term resulted in a recall of 6958 records. The Medline search routine breaks the 
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overall search results into various subheadings. This allows for the elimination of the 
undesired subheadings of the parent search term. The following subheadings were 
selected: 
• Classification 
• Economics 
• Ethics 
• History 
These together yielded a recall of 93 records, and a precision of 2. This is hereby referred 
to as result set A. 
Since Bioinformatics was not indexed as a subject heading, it could only be searched as a 
keyword. This search (Bioinformatics as keyword) yielded in Medline, a recall of 2110 
records. Using the “Combine” search tool, the two result sets were combined to show the 
intersection of the two sets. There were 26 common records (intersection) in this result 
set - B. The 2 records from A were among this set. 
Using the term “Medical Informatics” yielded 3098 records. Pertinent subheadings 
selected reduced this to 130 records (Classification, Economics, Ethics and History). 
Combining this result set with result set B yielded 1 journal article, “Bioinformatics and 
medical informatics: collaborations on the road to genomic medicine” by Kulikowski & 
Maojo. 
Introducing Pharmacogenomics as a search term in Medline revealed that the term is 
indexed under the heading Pharmacogenetics. This term is used for Pharmacogenomics 
and is related to Drug Resistance and Toxicology. It has been indexed since 1970 and is a 
branch of genetics which deals with the genetic variability in individual responses to 
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drugs and drug metabolism. Search term “Pharmacogenetics” gave a recall of 128 records 
(selected subheadings) and a precision of 3. A Boolean combination of the 
Bioinformatics and Pharmacogenetics yielded 0 results. 
Several other terms were introduced to explore the available literature on Bioinformatics 
and related disciplines. Such terms include Healthcare Economics, Healthcare 
Informatics, Pharmaceutical Industry, Drug Discovery, Drug Development, and 
Genomics among others. These were also searched in combinations. As an example, 
Drug Discovery (headings: Pharmacology or Biotechnology) yielded 17525 hits. A 
combination of this and the Pharmacogenetics result set yielded a recall of 16 records of 
which 3 were reviewed further.  
These same searches were carried out in the ABI/INFORM database (hereon after 
referred simply as ABI). The search for Bioinformatics in ABI resulted in 650 records of 
which 6 were found to be relevant to this thesis. Of the 6, 1 article was also part of the 
result set from the Medline search. The ABI search engine presented a few search terms 
as complements to the Bioinformatics keyword. These include (with the recall/precision 
numbers from searches carried out with these terms): 
• Bioinformatics AND Pharmaceutical Industry (36/3) 
• Bioinformatics AND Research & Development (33/3) 
• Bioinformatics AND Genomics (28/6) 
 
ERIC and EconLit did not generate many articles. A search using the term 
“Bioinformatics” resulted in 17 total articles. The precision on this was 2. After a few 
Boolean combinations of various search terms turned up no articles, the use of ERIC and 
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EconLit was discontinued. Serendipitous discoveries also added to the articles reviewed. 
When reviewing a selected article, some referenced articles and publications in that 
article were also sought and reviewed. The reference provides enough information for a 
focused search in the databases that allows for the article to be easily discovered – if 
indeed it exists in the searched database. 
 
Selection Criteria 
All searches were configured for English-language only articles and publications were 
mostly limited to articles from 1990 to 2004 with the exception of a few historical 
references such as “The cost of developing a new drug” by Steven Wiggins (1987) that 
was discovered serendipitously. The rationale behind the decision to focus only on 
articles written or published no earlier than 1990 is based on the assumption that the 
theory and practice of Bioinformatics and related technologies has only in very recent 
years gained prominence in the mainstream of scientific literature. Also, the Human 
Genome Project (HGP) which significantly catalyzed the theory and practice of 
Bioinformatics and related technologies was inaugurated in 1990. Bioinformatics and 
related technologies have evolved significantly in the time since the onset of the HGP 
such that literature prior to 1990 can potentially be obsolete. 
Selection was based on a variety of criteria. First was a review of the titles and the 
abstracts. This was the first gate for articles selected for further review.  The title of an 
article or publication sometimes can be misleading, so a review of the abstracts (abstract 
differentiation) gives a better indication of the coverage and scope of the article. The 
 29
review of abstracts allows for the summarized contents of an entire article or publication 
to be quickly evaluated. This enables a timely selection process. 
Ultimately, selection was based on the contents of the articles. A review of an article will 
show if the article is can add value to the thesis. The scope of the thesis was always put in 
consideration when these articles were reviewed. Not all articles that discussed 
Bioinformatics and related technologies were relevant to the thesis as the thesis primarily 
reviewed these in relation to the drug discovery and development process. In this regard 
many articles and publications reviewed were pertinent to the search terms used but were 
outside of the scope of this thesis. 
For the semi-structured interviews, a series of interviews were carried out with two 
practitioners in the field of Bioinformatics. These experts work in a prominent 
pharmaceutical company and are directly involved in the application of Bioinformatics 
techniques in the drug discovery and development process. The application of 
Bioinformatics techniques in the pharmaceutical industry is geared towards drug 
discovery through experimentation. It therefore falls within the classification of Research 
and Development (R&D).  R&D in the Pharmaceutical industry is highly confidential, 
proprietary and is a major component of intellectual property, and is not ready shared. 
The interviewees therefore requested anonymity and mostly confirmed or validated the 
information obtained from the literature review. Their perspectives however gave very 
useful insights into the way Bioinformatics is practiced in the field. With their express 
permissions, parts of their accounts have been rephrased and paraphrased for the purpose 
of this thesis. 
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CHAPTER 5 
RESULTS 
 
The findings of the literature review are reported in this chapter. The results are arranged 
in different contiguous sections. The chapter begins with a historical overview of the 
evolution of drug discovery and development. Next is a discussion of drug discovery and 
development, as is commonly practiced today. The costs and consequences of the current 
practice of drug discovery and development is discussed next, followed by a review of 
the impacts (and potential impacts) of Bioinformatics on this process. The specific impact 
of Pharmacogenomics is discussed to conclude the chapter. 
Drug Discovery and Development 
Drug Discovery and Development Today 
Drug discovery today is a very complex, competitive, delicate and risky process. This is 
partly because the pharmaceutical industry is the epitome of the ‘winner-takes-all’ 
philosophy where the first company to patent a drug gets exclusive rights for its use for 
many years - a passage way to huge financial gains (Duggan et al, 2000). The runner-up 
gets absolutely nothing (Duggan et al, 2000). The drug discovery, development and 
approvals process, from conception to market is summarized in Fig. 1 below.  
 
Fig 1: The Drug Discovery, Development and Approvals Process. 
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Drug companies continuously analyze thousands of compounds, seeking ones of 
therapeutic value (Klein & Tabarrok, 2003). Drug testing begins at the preclinical stage 
(Klein & Tabarrok, 2003; Wierenga & Eaton, 2004). In this phase, the manufacturer 
completes laboratory and animal studies of the compound, to show biological activity 
against the targeted disease and to verify the safety of the compound (Klein & Tabarrok, 
2003; Wierenga & Eaton, 2004). The preclinical testing phase lasts anywhere from three 
to seven years (Klein & Tabarrok, 2003; Wierenga & Eaton, 2004). Of five thousand 
compounds tested, approximately five will appear promising enough to induce the 
company to file an Investigational New Drug Application (IND) (Klein & Tabarrok, 
2003; PhRMA, 2003; Wierenga & Eaton, 2004). The IND shows results of previous 
experiments, how, where and by whom the new studies will be conducted; the chemical 
structure of the compound; how it is thought to work in the body; any toxic effects found 
in the animal studies; and how the compound is manufactured (Wierenga & Eaton, 2004). 
If the FDA approves the IND, an Institutional Review Board (IRB) is also required to 
give its approval before the manufacturer can be permitted to begin the first phase of 
development (Klein & Tabarrok, 2003; Wierenga & Eaton, 2004). The FDA strictly 
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monitors the membership of the IRB to ensure that it is composed of “at least five 
members including at least one scientific member, one nonscientific member, at least one 
person not affiliated with the research institution, no members with conflicts of interests, 
both genders if at all possible, and so forth” (Klein & Tabarrok, 2003). The IND stage 
consists of three phases: 
 
Phase I 
In phase I, the pharmaceutical companies conduct clinical trials using anywhere from 
twenty to a hundred healthy volunteers to determine the drug's basic properties and safety 
in humans (Pratap, 2004). This test stage can last for one to two years (PhRMA, 2003).  
 
Phase II 
 
In phase II, efficacy trials begin as the drug is administered to several hundred volunteer 
patients (Pratap, 2004). In this phase, the patients are given the drug to evaluate how 
effective it is against the observed signs and symptoms of the disease (Pratap, 2004). The 
possible side effects are also evaluated (Pratap, 2004). At the end of phase II, the 
manufacturer meets with the FDA to discuss the development process, continued human 
testing, any concerns the FDA may have, and the protocols for phase III, which is usually 
the most extensive and most expensive part of drug development (Klein & Tabarrok, 
2003). 
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Phase III 
Phase III testing involves one to several thousand patient volunteers and is by far the 
most detailed, time consuming and expensive clinical trial phase (Klein & Tabarrok, 
2003; PhRMA, 2003; Wierenga & Eaton, 2004). In this phase, the drug is administered to 
patients to get more information on its effectiveness, safety, optimal dosage and rare side 
effects (Pratap, 2004; Wierenga & Eaton, 2004). This essentially is a risk-benefit analysis 
that allows the FDA decide on the overall benefit of a drug, measured against the 
observed risks and side effects (Klein & Tabarrok, 2003).  
Once Phase III is complete, the manufacturer analyzes all of the data and files a New 
Drug Application (NDA) with FDA if the data successfully demonstrate safety and 
effectiveness (Klein & Tabarrok, 2003; Wierenga & Eaton, 2004). Mahlich (2001) 
describes a Phase IV where the new drug, having been successfully registered is 
continuously monitored “to collect and evaluate information on rare side-effects, to 
quantify the therapeutic risks and to determine possible new areas of indication”.  
During the IND phases (Phases I – III) there are a few accommodations that can be 
allowed the drug manufacturers. The manufacturer can receive an “accelerated 
development” status, to allow for the treatment of patients with “life-threatening or 
seriously debilitating conditions, for which no other drug treatment exists”, or a 
“treatment IND” status to allow for treatment of patients with “immediately life-
threatening” conditions (Klein & Tabarrok, 2003). The NDA must contain all of the 
scientific information that the company has gathered and typically run 100,000 pages or 
more (Wierenga & Eaton, 2004). Review of the NDA typically lasts one to two years, 
bringing total drug development and approval (that is, the IND and NDA stages) to 
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approximately nine years (Klein & Tabarrok, 2003). During the NDA stage, the FDA 
consults advisory committees made of experts to obtain a broader range of advice on drug 
safety, effectiveness, and labeling (Klein & Tabarrok, 2003). Once approved, the drug 
may be marketed with FDA regulated labeling (Klein & Tabarrok, 2003). The FDA also 
gathers safety information as the drug is used and adverse events are reported, and it will 
occasionally request changes in labeling or will submit press releases as new 
contraindications arise (Klein & Tabarrok, 2003). If adverse events appear to be 
systematic and serious, the FDA may withdraw a product from the market (Klein & 
Tabarrok, 2003). 
For every 5,000 or so compounds tested, approximately five will appear promising 
enough to file an IND (Klein & Tabarrok, 2003; PhRMA, 2003; Wierenga & Eaton, 
2004). Of those five, approximately one will be approved by the FDA and make it to 
market (Klein & Tabarrok, 2003; PhRMA, 2003; Wierenga & Eaton, 2004). 
For a detailed discussion of the drug development process, please refer to the FDA 
handbook on this subject (http://www.fda.gov/cder/handbook/develop.htm).  
 
Cost of Drug Discovery and Development 
Discovery, Development, Testing and Approval Costs 
In addition to the risk and uncertainties, the discovery process is a capital-intensive 
process, with ever increasing costs (Frank, 2003). There have been differing reports on 
the actual costs of drug development. Generally speaking, the cost of drug discovery and 
development is regarded as the total cost from discovery to approval (Klein & Tabarrok, 
2003; PhRMA, 2003; Wierenga & Eaton, 2004). Wiggins (1987), in his detailed study of 
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the costs of developing new pharmaceutical drugs showed a substantial and steady 
increase in the development costs. He reported the cost – at an annual inflation rate of 8% 
– to be about $54 million in 1976, increasing a decade later to $125 million in 1986 
dollars (Wiggins, 1987). The Tufts Center for the Study of Drug Development (CSDD) in 
2001 announced that the average cost of developing a new prescription drug was $802 
million. The same study had estimated the cost to be $231 million a decade earlier 
(CSDD, 2001). While this estimate, adjusted in 2003 to $897 million, seems to be the 
industry standard, the actual cost of drug discovery remains a topic for heated debate 
(Frank, 2003). Public Citizen (2002), a popular nonprofit consumer advocacy 
organization, referred to the 2001 estimate as the “US$802 million myth”. The 
organization claimed that the drug industry generally “exaggerates the cost of research 
and development for prescription drugs to justify high prices” (Public Citizen, 2002).  
DiMasi et al (2003) also refuted the $802 million estimate charging that it included 
“accounting for the time between investment and marketing”. After evaluating research 
and development costs of 68 randomly selected new drugs obtained from a survey of 10 
pharmaceutical firms, they proposed the real “out-of-pocket” estimate to be about $403 
million, a difference of almost $400 million (DiMasi et al., 2003). The Pharmaceutical 
Research and Manufacturers Association (PhRMA) however opined that the $802 million 
estimate was “likely to be conservative” stating that the real cost could be well above the 
CSDD estimate (PhRMA, 2001). This view was supported by the consulting firm, Bain 
and Co. in a December 2003 study, that estimated the costs to be approximately $1.7 
billion – more than twice the amount announced by the CSDD study just months earlier 
(Gilbert et al., 2003).  The following table shows the costs as proposed by the Bain and 
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Co. 
study.
 
Source: Gilbert et al. 
This new study included the money lost on failed drugs in the clinical trials stages, and 
money spent on sales and marketing – costs not included in the CSDD report (Gilbert et 
al., 2003; Mullin, 2003). Many in the drug industry however believe the CSDD estimate 
to be more accurate (Rogoski, 2004). The FDA concurs with the CSDD view and 
estimates the costs of drug development to be approximately $800 million with the 
process from synthesis to approval lasting approximately 15 years (FDA, 2001). While 
the debate rages on, one fact commonly agreed upon is that the costs of new drug 
development are enormous, and on the rise. A direct effect of the high and rising cost of 
drug development is the perception that a drug must be widely successful and be used by 
a large number of people (Drews & Duyk, 2004). 
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Collateral Costs  
As was noted in the previous section, the cost of drug discovery and development is 
generally regarded as the total cost from discovery to approval (Klein & Tabarrok, 2003; 
PhRMA, 2003; Wierenga & Eaton, 2004). There are however other costs that are 
associated with drug discovery and development. These include – among others – the 
costs of marketing and commercialization, costs to society as well as costs to 
pharmaceutical companies as a result of litigations.  
 
Commercialization Costs 
The study by Bain Co., which estimated the cost of drug development to be about $1.7 
billion included the money lost on failed drugs in the clinical trials stages, and money 
spent on sales and marketing – costs not included in the generally accepted cost estimate 
(Gilbert et al., 2003; Mullin, 2003).  Gilbert et al., (2003) estimate the average drug 
launch cost (post approval) to be $250 million.  
According to Tait & Mittra (2004), “the products that are easiest and cheapest to develop 
– and have the largest potential markets – have already been produced and are probably 
off patent or nearing that point.” Pharmaceutical companies in search of immediate 
profitability often focus on the development of these copycat “me too” drugs that address 
medical needs for which there are already drugs (Koppal, 2004). The sales and marketing 
costs are generally high in part because of the “intense promotional “noise” … needed to 
attract the attention of physicians and patients” who already have access to drugs that 
offer similar therapeutic benefits (Meyers & Baker, 2001).  
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Another group of collateral costs include costs associated with drug recalls and 
litigations. 
 
Drug Recalls and Litigations 
The pharmaceutical industry has experienced several withdrawals and recalls of drugs 
that have hitherto been approved for marketing (Bernard, 2003; Klein & Tabarrok, 2003; 
Tait & Mittra, 2004). This is often as a result of the emergence of previously unsuspected 
side effects, or in some cases after accusations of concealment of negative results from 
clinical trials (Klein & Tabarrok, 2003; Tait & Mittra, 2004). Either way, there usually is 
an enormous monetary consequence as investors quickly disinvest in the company (where 
such a company is publicly traded and shareholder owned) and patients flock to the 
courts with litigations for negligence and pharmaceutical malpractice (Simons et al., 
2004). In a 2003 study performed for the U.S. Chamber Institute for Legal Reform, 
Pendell reported that a large number of medical practitioners have avoided prescribing an 
appropriate prescription medication because they are aware that such medication may be 
involved in some product liability litigation (Pendell, 2003). Similarly, patients have 
stopped taking, or outright refused some medication when they discovered such 
medication was involved in some product liability litigation (Pendell, 2003). These 
together ultimately impact – negatively – the revenue potentials of such drugs (Pendell, 
2003) 
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Costs to Society 
According to a 1994 study, adverse drug reactions ranked between the fourth and the 
sixth leading causes of death among hospitalized patients (Lazarou et al., 1998). The 
authors of this analysis estimated that in 1994 alone, there were 2,216,000 adverse drug 
reactions of which 106,000 resulted in fatalities (Lazarou et al., 1998). Errors in drug 
administration, non-compliance, overdose and drug abuse were excluded from this 
analysis (Lazarou et al., 1998). This is all from adverse reactions to "safe," FDA-
approved drugs (Lazarou et al., 1998). A 1999 study by the Institute of Medicine (IOM) 
stated that “at least 44,000 people and perhaps as many as 98,000 people each year” die 
in hospitals from preventable medical errors (Kohn et al., 1999). The report indicated that 
“adverse drug events” was the leading contributor to the overall medical errors, which 
cost between $17 billion and $29 billion per year in hospitals nationwide (Kohn et al., 
1999). The current practice of drug development addresses the needs of the majority of 
the population. This strategy is counter to scientific data, which has shown that people 
vary in their response to the same drug due to differences in their genetic make-up 
(Nuffield Council on Bioethics, 2003; Evans et al. 1999, 2004; Prows & Prows, 2004). 
Prows & Prows (2004) observed that adverse drug reactions result in annual hospital 
expenditures estimated at $5.6 billion. These adverse reactions are also costly in terms of 
the loss of confidence in the healthcare system and a diminishing satisfaction for both 
patients and health professionals (Kohn et al., 1999). 
 
Consequences of Current Drug Discovery and Development Strategy 
The Blockbuster Drug Model 
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A blockbuster drug according to Drews & Duyk (2004) is one that is typically marketed 
for upwards of 20 million people, generating upwards of $1billion a year in sales (Drews 
& Duyk, 2004). The success of most blockbuster drugs is hinged on their being taken by 
a large number of people for long periods of time (Tait and Mittra, 2004). All drugs are 
required to go through the same approval process, whether or not the projected market 
was two million or twenty thousand people (Klein & Tabarrok, 2003). This means that 
with the current test and approval process, most drugs will take approximately the same 
time to get to market (Klein & Tabarrok, 2003), making the “blockbuster drug model” an 
attractive adaptation. The blockbuster drug model according to Keefer (2003) is that in 
which drug manufacturers “derive a majority of their revenue from the sales of a few 
individual patented products”. The need by the pharmaceutical companies to recoup the 
vast sums and still be profitable becomes paramount (Rioux, 2000; Michalowski, 2001). 
From this perspective, it may be inferred that the blockbuster syndrome is a consequence 
rather than a cause of the high discovery, development and approval costs (Klein & 
Tabarrok, 2003). While this may be debatable, the clear result of the high drug discovery 
and development costs is that pharmaceutical companies rely on blockbusters for their 
financial sustenance and growth (Rioux, 2000; Michalowski, 2001).   
The following table illustrates the results of the blockbuster model for the top 11 
pharmaceutical companies in the world in 2002. 
Table 1: ‘Blockbuster sales by major pharmaceutical companies, 2002 
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 This approach is investor driven and has been applied successfully in both the automobile 
and movie industries (Keefer, 2003). It is however causing a significant amount of 
economic pressure on the drug discovery and development process. In fact, Joe Chimera, 
PhD, the head of the Pharmaceutical Technology Group for BioSignia posits that “the 
pressure to maintain the existing types of margins to keep shareholders happy is forcing 
pharmaceutical companies to focus their efforts on developing at a minimum one or two 
big blockbusters a year” (Keefer, 2003). The blockbuster model has also resulted in a 
sharp decline in pharmaceutical innovations (Whittaker, 2003). According to Tait and 
Mittra (2004), the drugs that are “cheapest to develop – and have the largest potential 
markets have already been produced and are either off-patent or nearing that point”. This 
position is collaborated by Frank (2003) and Whittaker (2003). Frank (2003) observed 
that of the 98 NDA applications approved by the FDA in 2000, only 27 (about 28%) were 
for New Molecular Entities (NME) i.e. new chemical entities that have not hitherto been 
tested in humans in a quest to seek drug approval. The rest of it was for “products that 
represent new formulations and new methods of delivering existing drugs” (Frank, 2003). 
 42
These ‘new’ drugs have variously been described as “less new” (Frank, 2003), “follower” 
(Rasmussen, 2003) and “me-too” (Koppal, 2004). The bottom line is they have resulted 
in an “innovation gap” in the pharmaceutical industry resulting in unmet medical needs 
remaining unmet (Whittaker, 2003).  
Besides the innovation gap, there are other problems that have resulted from the 
blockbuster drug model. These include the emergence of “orphaned” drugs (drugs for 
rare diseases that are overlooked or lost in the quest for the blockbusters), and the 
consequences of patent protection. These are discussed in the following sections. 
 
Orphan Drugs 
A direct consequence of the innovation gap is what Klein & Tabarrok (2003) have 
described as “drug loss”. Drug loss, simply put, is the reduction in the total number of 
new drugs created due to various reasons including the delay in drug approvals as well as 
the dogmatic quest for blockbusters (Klein & Tabarrok, 2003). The effect of the drug loss 
phenomenon is felt mostly in drugs for rare diseases (Klein & Tabarrok, 2003).  
Orphan drugs are those designed for diseases or conditions affecting less than two 
hundred thousand persons in the United States at the time of designation (FDA, 1999). 
These diseases that fall in this category are usually classified as “rare diseases” (Klein & 
Tabarrok, 2003). Alternatively, these diseases or conditions can affect more than two 
hundred thousand persons but the costs of developing the curative drugs cannot be 
recouped within seven years from sales in the United States (FDA, 1999). In the quest for 
the blockbusters, many small-market therapies – drugs designed for sub-groups of the 
general population – are abandoned or orphaned (Klein & Tabarrok, 2003). The medical 
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needs that these could meet remain mostly unmet. The Orphan Drug Act of 1983 was 
promulgated to address this problem (FDA, 1999). The idea was to help alleviate the 
costs incurred by the manufacturers of orphaned drugs by giving them “tax breaks, 
subsidies, and special exclusivity privileges” as “sponsors of drugs for rare diseases” 
(Klein & Tabarrok, 2003). Several abuses of the Orphan Drug incentives have been 
reported (Richardson, 1987; Kenney, 1988). While the Orphan Drug incentives are given 
based on expected US sales, Klein & Tabarrok (2003) note that “worldwide sales often 
much exceed U.S. sales” thereby effectively negating the need for such incentives. 
Overall, the Orphan Drug act has not been very effective in the prevention of drug loss. 
Its intentions though noble have in reality been significantly more beneficial to the 
established U.S. drug manufacturers, resulting in a multiplication of their monopoly 
privileges (Arno et al., 1995; LeBlanc et al., 1996). 
 
Patent Protection 
If the U.S. government grants a patent to a drug, all other manufacturers are barred for a 
predefined number of years from producing a product of the same chemical composition, 
except by permission from the patent holder (Klein & Tabarrok, 2003). The patent 
protection term for a drug in the US is usually 17 years (FDA, 2001; Klein & Tabarrok, 
2003). A patent grants a degree of monopoly power to the patent holder. When 
developing a new drug, pharmaceutical companies are usually anxious about the 
possibility that another company may also be working on the drug or similar NCE, or has 
received news or leaks about the promising incipient drug. They are therefore eager to 
obtain a patent. Companies therefore apply for and receive drug patents in advance of 
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final FDA approval to market the drug (Grabowski & Vernon, 1983; Klein & Tabarrok, 
2003). Some of the seventeen years of patent protection is therefore dissipated waiting for 
approval (Grabowski & Vernon, 1983). The "effective patent life" of a new drug is the 
time from approval to the end of the patent (Grabowski & Vernon, 1983; Gilbert et al., 
2003; Klein & Tabarrok, 2003). When a patent expires, other producers are permitted to 
replicate the product and to sell it as a "generic drug." This competition drives down 
prices (Gilbert et al., 2003; Klein & Tabarrok, 2003). The 1984 Drug Price Competition 
and Patent Term Restoration Act, known as the Waxman-Hatch Act further served the 
generic drug producers by removing some arbitrary constraints on generic drug 
development (Klein & Tabarrok, 2003). In general, rising prices as well as aggressive 
patent challenges by competitors limit the total revenue potential of the blockbuster drug 
(Gilbert et al., 2003) 
Bioinformatics and Pharmacogenomics 
Bioinformatics in Drug Discovery and Development 
Traditionally, pharmaceutical companies have employed a cautious mostly chemistry and 
pharmacology-based approach to drug discovery, and are finding it “increasingly difficult 
to find new compounds that will lead to new drugs” (Lim, 1997; Duggan et al., 2000). In 
the highly competitive  “winner takes all” pharmaceutical industry, the first company to 
patent a new chemical entity (NCE) for a particular therapy takes all the spoils, leaving 
other competitors to mostly wait for patent expirations to partake in the largesse (Duggan 
et al., 2000). Pharmaceutical companies therefore invest heavily in any processes that can 
accelerate any step of the drug development cycle (Lim, 1997; Van Arnum, 1998; 
Papanikolaw, 1999; Overby, 2001; Whittaker, 2003). The increasing pressure to generate 
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more drugs in less time has resulted in remarkable interest in Bioinformatics 
(Papanikolaw, 1999). 
Although Bioinformatics attained prominence because of its leading role in the storage, 
management and analysis of genomic data, its focus seems to be shifting due to the need 
of the life sciences to exploit these data (Whittaker, 2003). According to Overby (2001), 
technologies grouped under the umbrella of Bioinformatics involve the use of computers 
to store, organize, generate, retrieve, analyze and share genomic, biological and chemical 
data for Drug Discovery. Several other writers have made the connection between 
Bioinformatics and Drug Discovery. Whittaker (2003) posited that Bioinformatics is used 
in “drug target identification and validation and in the development of biomarkers and 
toxicogenomic and pharmacogenomic tools to maximize the therapeutic benefit of 
drugs”. Ratti & Trist, (2001) suggest that “today’s [drug discovery and development] 
process … has been enriched by advances in technological developments in screening, 
synthetic chemistry, and by the increased number of possible targets due to the 
application of genomics and bioinformatics.” The traditional chemistry and 
pharmacology-based approach to drug discovery has recently given way to a more 
modernized information-based approach – Bioinformatics (Lim, 1997). The drug 
discovery and development landscape has changed – for good, with the practice of 
Bioinformatics becoming prevalent in the drug industry such that the drug industry is one 
of the major players guiding the development of the Bioinformatics field (Van Arnum, 
1998; Duggan et al., 2000; Attwood & Miller, 2003). Duggan et al, (2000) observed that 
“many (if not all) of the large pharmaceutical companies have established internal 
bioinformatics groups whose purpose is to beat the competition to solutions of a problem 
 46
that may give their company that crucial edge in producing the next major drug.” 
Bioinformatics has certainly come to stay and is now ubiquitous with drug discovery. 
According to Pollock and Safer (2001) “few if any (drug discovery) projects are 
computer free”. The impacts that Bioinformatics has had and continues to have in the 
early stages of drug development are encouraging and would only lead to further 
Bioinformatics investments (Ratti & Trist, 2001). Wentland (2004) provides a graphical 
illustration of the role of Bioinformatics in drug discovery: 
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Fig. 1: The Role of Bioinformatics in Drug Discovery 
 
 Source: Wentland (2004) 
 
One of the main thrusts of current Bioinformatics methods is the finding of biologically 
active candidates (Whittaker, 2003). Drugs are usually only developed when the specific 
drug target for those drugs’ actions have been identified and studied (Lim, 1997). Until 
recently, drug development was restricted to a small fraction of possible targets since the 
majority of human genes were unknown. The number of potential targets for drug 
development is increasing dramatically, due mainly to the genome project (Lim, 1997). 
Mining the human genome sequence using Bioinformatics has helped define and classify 
the genomic compositions of genes coding the target proteins, in addition to revealing 
new targets that offer potential for new drugs (Van Arnum, 1998; Southan, 2001; Foord, 
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2002).  This is an area where the human genome information is expected to yield big 
payoffs (Southan, 2001; Foord, 2002). Drug developers are presented with an 
unaccustomed luxury of choice as more genes are identified and the drug discovery cycle 
becomes more data-intensive (Lim, 1997).  Of the estimated 35,000 genes in the human 
genome, Zambrowicz & Sands (2003) contend that the 100 top-selling drugs have 
targeted only 43 of their encoded proteins. By enabling the identification and analysis of 
more and more drug targets, Bioinformatics is expected to greatly increase the breath of 
potential drugs in the pipelines of pharmaceutical companies (Lim, 1997; Overby, 2001; 
Whittaker, 2003; Zambrowicz & Sands, 2003). 
 
After drug targets – or better still, “potential” drug targets – have been discovered, there 
is an invaluable need to establish a firm association between a putative target gene or 
target protein with the disease of interest (Whittaker, 2003). The establishment of such a 
key relationship provides justification for the drug development. This process, known as 
target validation, is an area where Bioinformatics is playing a significant role.  Target 
validation not only helps build the case that the drug modulation of such a target will 
result in beneficial effects on the disease, it also helps mitigate the potential for failure in 
the testing and approval phases (Ratti & Trist, 2001; Gilbert et al., 2003; Whittaker, 
2003).  
 
The current high cost of drug discovery and development is a major cause for concern 
among pharmaceutical companies (Papanikolaw, 1999). Along with increasing 
productivity, pharmaceutical companies always aim to reduce the high failure rate in the 
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drug discovery process thereby increasing the number of drugs coming to market 
(Papanikolaw, 1999). The cost of clinical trials limits the number of drugs a 
pharmaceutical company can develop, and hence selecting the compounds with the best 
chances for approval is critical (Klein & Tabarrok, 2003; PhRMA, 2003; Wierenga & 
Eaton, 2004).  The costs of drug discovery and development – generally include total 
costs from discovery to approval (Klein & Tabarrok, 2003; PhRMA, 2003; Wierenga & 
Eaton, 2004) though some studies have included the costs of failed drugs and the costs 
for commercialization (Gilbert et al., 2003). There is also a cost associated with the 
elongated process, beginning from discovery all the way to final approval (Lim, 1997; 
Klein & Tabarrok, 2003; PhRMA, 2003). Advances in Bioinformatics have allowed for 
marked efficiencies, beginning with target identification and validation, to assay 
development, and high-throughput screening (HTS) – all with the goal of identifying new 
chemical entities (Belkowski, 2003). With more efficient target discovery and validation, 
Bioinformatics can help ensure that more drug candidates are successful during the 
approval process as well as shortening the discovery and development cycle, making it 
more cost-effective (Lim, 1997).  
 
There are some other non-discovery/development costs – collateral costs – that plague the 
pharmaceutical industry. These costs include commercialization costs (Gilbert et al., 
2003; Mullin, 2003), litigation and drug-recall costs (Klein & Tabarrok, 2003; Tait & 
Mittra, 2004), and general costs to society (Lazarou et al., 1998; Kohn et al., 1999). 
Commercialization costs, estimated by Gilbert et al., (2003) to be about $250 million per 
approved drugs, are high mainly because most “new” drugs approved are essentially 
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functional replicas of drugs that already exist (Koppal, 2004; Tait & Mittra, 2004). 
Because these mostly copycat drugs are being commercialized to abate ailments for 
which there are already drugs, there is a need for what Meyers & Baker (2001) describe 
as a high and “intense promotional noise” in their (pharmaceutical companies) efforts to 
attract the attention of both patients and physicians who already have access to similar 
medication. Bioinformatics, by enabling the more efficient discovery and identification of 
drug components and targets, will bridge the innovation gap, thereby allowing 
pharmaceutical companies the opportunity to efficiently discover and develop novel 
drugs and chemical entities (Whittaker, 2003). Commercialization costs are then expected 
to fall significantly, as drugs are commercialized not in competition with already existing 
equivalents, but in announcement and advertisement of new drugs that offer new 
therapeutic benefits for hitherto unmet medical needs (Meyers & Baker, 2001)  
 
Pharmacogenomics in Drug Discovery and Development 
The new knowledge of genetic biomarkers for diseases is spurring the development of 
pharmacogenomic-based drugs discovery and development strategies that allow 
pharmaceutical companies design more individualized drug regimens and dosages 
(Wechsler, 2004). This is accomplished by identifying genetic conditions that allow 
individuals to be more likely to respond to certain drugs, not respond at all or be 
susceptible to adverse reactions (Bernard, 2003; Whittaker, 2003; Wechsler, 2004). 
Several studies have cited adverse drug reactions to be one of the leading causes of death 
among hospitalized patients, contributing the majority of the $17 to $29 billion annual 
costs of medical errors (Lazarou et al., 1998; Kohn et al., 1999; Prows & Prows, 2004). 
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Kohn et al., (1999) also note the cost associated with the loss of confidence in the 
healthcare system and the diminishing satisfaction of both patients and health 
professionals. 
 
Pharmacogenomics is expected to reverse this trend by enabling pharmaceutical 
companies to design drugs that meet the needs of pre-defined genetic sub-groups of the 
general population (Rioux, 2000). Pharmacogenomics cannot and does not improve the 
efficacy of a given drug; it simply helps in selecting patients who are likely to respond 
well (Rioux, 2000). The main interest is in identifying patients for whom drug efficacy 
can be predicted, and to spare others from avoidable adverse effects (Rioux, 2000). The 
promise of pharmacogenomics is that physicians may soon be able to prescribe drugs on 
the basis of their patients’ genetic profiles (Prows & Prows, 2004; Zemlo, 2004). This 
would take away the guesswork in drug prescriptions, increase both physician and patient 
confidence and radically modify the prevailing approaches to drug discovery and 
development, diagnostics, therapies and disease prevention strategies (Prows & Prows, 
2004; Zemlo, 2004). There is also a benefit to society as the use of expensive drugs is 
avoided in patients whose ailments clearly would not have been abated or cured by these 
drugs (Rioux, 2000). 
 
As noted earlier, adverse drug reactions in the general population often results in 
hospitalizations and in some cases fatalities (Lazarou et al., 1998; Kohn et al., 1999; 
Prows & Prows, 2004). When these drug reactions are investigated and documented, and 
the culprit drug identified, the result commonly is a withdrawal (or recall) of the drug 
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(Bernard, 2003). This is immediately followed by a torrent of lawsuits for negligence and 
pharmaceutical malpractice (Simons et al., 2004). A pharmacogenomic drug development 
strategy presents an opportunity to reverse this trend (Bernard, 2003; Zemlo, 2004). The 
promise of pharmacogenomics may lead to the “accelerated development of precision 
pharmaceuticals” (Zemlo, 2004). Precision pharmaceuticals refer to drugs (and dosages 
of these drugs) that are tailored to an individual’s genetic composition (Bernard, 2003; 
Zemlo, 2004). These drugs according to Zemlo (2003) can be can be evaluated in 
simplified and shortened clinical trials and because of their customization will show little 
or no adverse effects. With drug customizations, some form of genetic testing or 
verification may be required prior to prescription (Bernard, 2003). This ensures that the 
chances for wrong prescriptions are greatly minimized (Bernard, 2003).  
 
In the course of drug discovery and development, pharmaceutical companies stay mostly 
focused on the major blockbuster drugs that are prescribed to upwards of 20 million 
people (Klein & Tabarrok, 2003; Drews & Duyk, 2004; Tait and Mittra, 2004). The result 
of this is a drug loss – a loss of drugs that may have been developed to cure diseases that 
affect only a small number of people (Klein & Tabarrok, 2003). These drugs – or 
potential drugs are abandoned or orphaned ((Klein & Tabarrok, 2003). A 
pharmacogenomic strategy to drug development may revive these orphaned drugs if it 
can be demonstrated that there are potential beneficiaries for these drugs (Bernard, 2003). 
Similarly, Rioux (2000) has suggested that “From an economics standpoint, if the 
pharmaceutical company could benefit from something like orphan drug status for its 
product, this would help encourage stratification of populations on the basis of 
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pharmacogenomics, since the reduction in the size of a population to be treated could be 
offset by preference for the drug”. This according to Rioux (2000) is the only way that 
pharmaceutical companies can be encouraged to forgo the blockbuster dogma. 
 
The FDA in recent years has recognized and even encouraged Pharmacogenomic 
approaches to drug discovery and delivery (Rioux, 2000; Wechsler, 2004). As 
pharmacogenomic technologies continue to emerge and mature, the FDA as well as other 
international regulatory bodies is developing pharmacogenomic guidelines and 
regulations (Bernard, 2003). In fact, the FDA is encouraging pharmaceutical companies 
to conduct pharmacogenomic research and submit results to a proposed “Interdisciplinary 
Pharmacogenomic Review Group” – a group that isn’t directly involved in the drug 
approval process (Bernard, 2003). Notwithstanding the increased attention and the 
documented potential and promise of pharmacogenomics-based drug development 
strategies, there has been continuous resistance to this approach on the part of 
pharmaceutical companies (Rioux, 2000; Bernard, 2003; Wechsler, 2004). This 
resistance is borne out of the perception that a pharmacogenomics strategy will lead to a 
significant loss of revenues resulting from the fragmentation of the drug market (Rioux, 
2000; Bernard, 2003). Bernard (2003) in his article “The 5 Myths of Pharmacogenomics” 
lists as the 4th myth, the perception that pharmacogenomics will diminish the much 
coveted blockbuster drug model. He goes on to debunk this “myth” by demonstrating the 
potential market-increase impacts of pharmacogenomics. In the diagram below, Bernard 
(2003) shows a holistic representation of the possibilities with pharmacogenomics. 
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Bernard (2003) clearly indicates that a pharmacogenomic strategy may or may not reduce 
a drug’s market size, and actually has the potential to increase it, depending on a variety 
of factors. For a full review of the factors illustrated in the chart above, please refer to 
“The 5 Myths of Pharmacogenomics”  (Pharmaceutical Executive. Eugene: Oct 
2003.Vol.23, Iss. 10;  pg. 70) 
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CHAPTER 6 
DISCUSSION AND FUTURE WORK 
 
This chapter is a review of the stated purpose, and a discussion of the results reported in 
previous chapters.  
In summary, the stated aims of this thesis are as follows: 
• To review the historical trend and evolution of the drug discovery and 
development process  
• To review the current model of cost evaluation of the drug discovery and 
development process.  
• To understand the propositions of a Bioinformatics and Pharmacogenomic 
approach to tailored and targeted drug discovery 
• To review the differences between the traditional approach and the 
Bioinformatics approach to drug discovery and development 
 
The findings of the literature review have been presented in the previous chapter. 
A review of the history of drug discovery and development reveals a process that has 
greatly evolved over time. Papanikolaw (1999), Ratti & Trist (2001) and Boa (2003) 
describe a process driven – up till the mid 20th century – mainly by trial and error, 
intuition and serendipity of chemists, biologists and physicians. During the second half of 
the 20th century, the pharmacological bases of drugs and diseases were beginning to be 
defined, leading to a more rational linear drug development process. In vitro methods 
(experiments carried out using animal tissues, but in an artificially simulated 
environment) gradually replaced the more invasive in vivo methods allowing for a higher 
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economy of scale in experimentation. Drug discovery today has generally followed this 
trend, though a significant amount of emphasis is placed not only on the efficacy, but also 
on the safety of the discovered and developed drug. The drug discovery process today is 
very heavily regulated, mainly to ensure the safety and protection of the general 
population. A major obstacle to the goal of drug safety is the inherent genetic variations 
in the general populations. Rioux (2000) has described this variation – generally referred 
to as genetic polymorphisms – as a “stable difference in DNA sequence at the same locus 
(a specific position in the genome) among individuals”. This difference is essentially 
what makes very few drugs to be effective for everyone. Hence, in the U.S., despite the 
elaborate testing and approval process as instituted by the FDA, Lazarou et al. (1998), 
Klein & Tabarrok (2003), Evans et al. (1999, 2004) and Prows & Prows, (2004) report 
adverse effects from supposedly “safe” FDA approved drugs – adverse effects that 
sometimes lead to fatalities. Mahlich et al, (2001) and Klein & Tabarrok, (2003) observe 
that the development, testing and approval process has increased from about 8 years in 
1960 to approximately 15 years in 1996 due mainly to the more stringent safety 
requirements imposed by the FDA during toxicity testing.  
There appears to be a conflict or disconnect between the full or intensive application of 
Bioinformatics in drug discovery and development and the expectations from the 
regulatory bodies. Though the FDA has – in principle, encouraged and in fact promoted 
pharmacogenomic testing during the discovery and development process, the regulatory 
machinery has not been put in place to fully support such initiatives. Primarily, 
pharmaceutical companies may benefit from a shortened testing and approval process to 
allow for their drugs to enter the market quicker. The shortened length of the approval 
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process can be justified by the fact that the target market for the concerned drug has been 
clearly and specifically defined along the lines of genetic composition. In the documented 
evolution of the drug discovery and development process, the position of this thesis is 
that the regulations need to be reformed to allow the full integration of the advanced 
Bioinformatics technologies in the drug discovery process. When this happens, the 
concept of personalized drugs may transform from myth to reality. 
 
The variations in the genetic composition among individuals in the general population 
was further revealed by the findings of the Human Genome Project – a project funded by 
the U.S. Government with the primary charge to research and document the genetic 
composition of the human being. The results from the Human Genome Project (HGP) 
further accentuated the knowledge of the differences in nucleotide sequences of 
individual DNA, and the effects of such differences. This newfound knowledge further 
elucidated the genetic bases of health and disease conditions.  
With the partial completion of the HGP in April 2003, Bioinformatics received a high 
amount of recognition in the scientific community. While it initially attained prominence 
because of its central role in the genome data storage, Whittaker (2003) notes that 
Bioinformatics has shifted focus as the life sciences attempt to exploit the data generated 
from the HGP. The pharmaceutical industry is perhaps the earliest and most ardent 
adopter of Bioinformatics and related technologies. Two chief challenges facing the 
pharmaceutical industry were identified in this thesis. They are:  
• The high cost of drug discovery and development, arising mainly from the 
extensive and time consuming trial and approval process, and  
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• The innovation gap - arising mainly in the quest to produce widely applicable 
blockbuster drugs – drugs that address needs for which there are already 
therapies. 
The high and rising cost of drug discovery and development has been highlighted in this 
thesis. Pharmaceutical companies, in competition continue to invest more and more 
resources in their respective bids to develop the next commercial blockbuster. A 
significant portion of the high cost is as a direct result of the time and resource intensive 
trials and approval process.  
The high cost of drugs is passed on to society, the end users of the drugs, and can have 
very far-reaching ripple effects on the society. Though the costing of the drug discovery 
and development process is a controversial subject, the effects of the high costs of the end 
product are often clear-cut. For example, a high cost for newly approved drugs would 
result in an increase in the cost of insurance to cover these drugs, in cases where these 
drugs must be prescribed and consumed. An increase in any insurance costs can 
potentially affect the attitudes of employers towards employees. Some analyses have 
shown that the high cost of insurance can translate to the high cost for employers who 
often are required to provide such benefits to their employees. In order to avoid incurring 
high costs for benefits such as employee insurance, employers have been known to resort 
to out-sourcing jobs to countries where they do not have to provide such benefits. 
Bioinformatics is expected to contribute to cutting down the costs of drug discovery and 
development, therefore resulting in cheaper medication and by implication, more 
affordable health insurance. Burke et al, (2004) and Prows & Prows (2004) note the high 
interest expressed by health insurance companies to a pharmacogenomic approach to 
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drug discovery, and suggest this to be and indication that they (the health insurance 
companies) believe this approach may lead to an overall decrease in the cost of 
healthcare. This perspective needs to be emphasized. The position of this thesis is that the 
cost-savings effect of Bioinformatics and related technologies need to be further and fully 
explored. The cost of drugs and healthcare is a very serious topic of public and political 
debate. This is ample justification for future work in this area. 
 
Another effect of the lengthy drug discovery and development process is the relatively 
quick expiration of patent protections, and the introduction of generic drugs. 
In the pharmaceutical industry, patents have to be taken out at a fairly early stage of drug 
development. This means that every additional day spent in drug development is a day 
lost in revenues under patent protection. In the U.S. patent protection for new chemical 
entities are usually given for a period of 17 years. Depending on when a pharmaceutical 
company applies for and receives patent protection, the 15-year (average) drug discovery 
and development period can erode much of the protection such that the effective patent 
protection time – the period from when the drug is approved and marketed to the end 
period of the patent – is significantly shortened. The patent protection is meant to give the 
original manufacturer a market exclusivity to enable such a company substantially recoup 
the high development costs and benefit from its “intellectual property”. The reviewed 
literature did not sufficiently address the impact that Bioinformatics and 
Pharmacogenomics can have on the patent protection that pharmaceutical companies 
receive. This subject matter is one that needs to be evaluated further. With the 
implementation of a Bioinformatics and Pharmacogenomics strategy, it is expected that 
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the drug development time frame and costs will be significantly reduced. If 
pharmaceutical companies are spending less time and money to develop drugs, perhaps 
the patent protection time periods ought to be reduced to allow quicker introduction of 
generic equivalents. While proponents may cite the advantages of competition, as 
manufacturers of generics are opportune to introduce their cheaper brand-name 
equivalents sooner, giving consumers the opportunity to select cheaper drugs without 
losing on efficacy. The stringent testing requirements for new drugs are mostly waived 
for the generic equivalents making them even cheaper to develop and market. They 
usually have the exact same chemical composition as the brand-name versions and are 
favored by many health insurance providers. Opponents will decry the shortening of an 
already “short” patent protection period. Besides, they will likely propagate the notion 
that the manufacturers of generics are benefiting unduly from the expense incurred by the 
original drug manufacturer. 
  
Bioinformatics and Pharmacogenomics are also expected to close the innovation gap 
leading to a wider array of truly new drugs. A good indication of the innovation gap is the 
availability of 3 high-profile drugs for erectile dysfunction (ED). When Pfizer in 1998 
introduced Viagra as a cure for ED, it was geared to capture and dominate a huge market 
of an estimated 30 million sufferers in the U.S. alone. After 5 years of market monopoly, 
two rivals were introduced in quick succession. GlaxoSmithKline PLC and Bayer AG 
introduced Levitra in August of 2003, with Eli Lilly and Icos Corp. following suite with 
Cialis in November of 2003. Viagra, Cialis and Levitra each are effective on 70 percent 
to 80 percent of men, but at different speeds. All three drugs work similarly – they block 
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an enzyme called PDE-5, which helps relax the penis and allow the blood flow needed to 
produce an erection. The rival companies have had to spend millions of dollars to market 
the differences among their drugs. Cialis rang up U.S. sales of $203 million in its first full 
year and had a $165 million advertisement expenditure. Levitra sold just $128 million 
worth of pills, well below what the manufacturers spent on TV, print and other media. 
Though there are differences in the ways that these drugs operate, they essentially cure 
the same condition leading to the same end results. The gargantuan advertisement 
budgets of these “me too” drugs is not yielding the desired results. With the introduction 
of Bioinformatics, literarily thousands of hitherto unknown drug targets have been 
identified in the human genome. Drugs can be developed to address very specific 
diseases based on the genetic composition of its sufferers. This thesis foresees the result 
to be the diversification of pharmaceutical companies’ drug profiles and a movement 
away from the blockbuster approach. 
 
The emergence of Bioinformatics and related technologies was widely believed to be the 
precursor for the age of targeted and tailored drug development. The testing and approval 
process would be shortened and the failure rate significantly reduced as drugs are 
designed for specific sub-sets of the population who have been identified and tested. 
Several writers alluded to the potentials of Bioinformatics and projected the development 
of subpopulation-specific drugs – drugs that would be tailored to meet the needs of sub-
groups, stratified according to their genetic compositions. More specifically, 
Pharmacogenomics, as projected, would combine pharmacology with Bioinformatics to 
yield what Zemlo (2004) described as “precision pharmaceuticals”. The development for 
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drugs for sub-groups of the general population has generated concern among 
pharmaceutical companies as this signifies a shift from the current practice. The coveted 
blockbuster drugs strategy is perceived to be at risk with the emergence of sub-population 
specific drugs. Bernard (2003) however described a system where the introduction of 
Bioinformatics would potentially increase the market share of a pharmaceutical product. 
For as much attention that Bioinformatics has received in recent years, the impact has 
been, in the most part, slow in manifesting. Lindpainter (2003) observed that “…the 
interface between genetics/genomics and pharmacology, pharmacogenetics and 
pharmacogenomics…. are commonly touted as heralding a ‘revolution’ in medicine, yet 
as soon as one begins to probe more carefully, little substance is yet to be found to 
support these enthusiastic claims”. Most of the enthusiastic projections remain just that – 
enthusiastic projections. 
There are a handful of exceptions. One outstanding example is the Genetech drug, 
Herceptin (trastuzumab), the product approved by the FDA in September 1998 for use in 
women with metastatic breast cancer who have tumors that overexpress the HER-2 
protein. This represents only about 25% of women with breast cancer. In the course of 
the testing and approval process, it was recognized that the drug did not meet the needs of 
the general population. It was therefore doomed for failure. Buoyed by public advocacy, 
Genetech saved the “failing” drug by coupling it with a pharmacogenomic test – 
HercepTest, to identify potential responders. The approval of this drug for marketing is 
an indication that pharmacogenomic approaches to drug discovery and delivery are being 
recognized. It is a striking example of how identifying patient-population subsets can 
bring a new measure of safety and efficacy. 
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As observed earlier, this measure needs to be expanded across the board to allow for the 
full integration of Bioinformatics and related technologies into the drug discovery and 
development process.  
 
Conversely, there are several cases where the genetic differences in the general 
population have negatively impacted a drug’s commercial success. Bayer’s cholesterol 
agent Baycol, Wyeth’s appetite suppressant Redux, GlaxoSmithKline’s oral diabetes 
agent Rezulin and more recently Merck’s arthritis drug Vioxx are some of the very recent 
drug withdrawals. Mainly because these drugs have been designed, developed and 
marketed for the general population, adverse reactions from a very small section of the 
population would sometimes lead to the withdrawal of a drug. As an example, the FDA 
in 1998 forced Hoechst Marion Roussel (now Aventis) to withdraw its $600 million-a-
year anti-allergy drug Seldane (terfenadine) from the market because less than 0.5 
percent of the population has a variant of the CYP3A gene that makes them unable to 
metabolize the drug in the presence of erythromycin, an antibiotic. These people usually 
suffered severe cardiotoxicity. A pharmacogenomic test, as was the case of Herceptin, 
may have kept the drug in the market.  
 
Besides limiting the incidents of drug withdrawals, a pharmacogenomic approach will 
also mitigate the incidence of orphaned drugs. Most drugs become orphaned during the 
testing and approval process when it becomes apparent – thanks to the non-responders in 
the general population – that they cannot be effective or in many cases injurious to 
certain groups of the population. If the responder groups are identified in the same way, 
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these drugs could be evaluated and approved following simplified clinical trials, as the 
identified responders would show very little or no side effects and/or unwanted 
complications. 
 
Bioinformatics and Pharmacogenomics have more potential than the current results have 
shown. McHale (2003) attested to this when he noted that Bioinformatics has not yet 
begun to have the impact on discovery that it can have. He cited the reasons to include a 
lack of standards, ontology and technological integration. The lack of standards and 
ontology was particularly apparent during the review of literature for this thesis. There 
are almost as many definitions of Bioinformatics (and related technologies) as there are 
Bioinformatician (also referred to as Bioinformaticists). There are often divergent views 
of the discipline and an absence of a hierarchical structuring of knowledge in the genre. 
Though this could be associated with the fact that the discipline is still relatively new in 
scientific literature, there is an urgent need to ensure that practitioners are “speaking the 
same language”. This will allow for better collaboration and integration with other 
disciplines. In fact, McHale estimated that a better defined and organized Bioinformatics  
combined with Chemical Informatics (Cheminformatics) will yield an integrated drug 
discovery informatics solution that could lead to an estimated $282 million potential 
savings per drug. 
 
Finally, Bioinformatics and Pharmacogenomics are the latest facets of the continuous 
evolution of the drug discovery and development process. Their adoption in the drug 
discovery and development process is synonymous with the future survival of the major 
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pharmaceutical companies. According to Zemlo (2004), Pharmacogenomics should be 
considered as the gateway by which 21st century medicine is ushered into the present. 
This gateway however is only wide enough to allow the harbingers of change. 
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